IPSC CENTURY THERAPEUTICS INC

Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:

  • Fireside Chat on Tuesday, April 30, 2024, at 1:30pm ET
  • Panel titled “iPSCs Unleashed: Mastering Manufacturing for Next-Gen Cell Therapies” on Tuesday, April 30, 2024, at 3:30pm ET

A replay of the events will be available on the “Events & Presentations” page in the “Investors” section of the Company’s website at  and will be available for 90 days following the events.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune and inflammatory diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune and inflammatory diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune and inflammatory disease care. For more information on Century Therapeutics please visit .

For More Information:

Investors/Media: Julie Seidel/ Noor Pahlavi –



EN
23/04/2024

Underlying

IPSCCENTURY THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTURY THERAPEUTICS INC

 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medici...

Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows: Fireside Chat...

April 23, 2024 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics Strengthens Position in Autoimmune Disease with S...

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026 Acquisition of Clade Therapeutics s...

April 11, 2024 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-d...

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024. The posters highlight the Company’s en...

April 8, 2024 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell...

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET. A replay of the event will be available on the “Events & Presenta...

March 19, 2024 1 EN
 PRESS RELEASE
Free
IPSC CENTURY THERAPE...

Century Therapeutics Reports Full Year 2023 Financial Results and Prov...

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to initiate Phase 1 CALiPSO-1 clinical trial in the first half of 2024 - - S...

March 14, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch